Back to Search
Start Over
COVID-19: New disease mechanism is simultaneously a therapeutic target.
- Source :
-
Memo [Memo] 2022; Vol. 15 (2), pp. 100-101. Date of Electronic Publication: 2022 Jun 07. - Publication Year :
- 2022
-
Abstract
- Competing Interests: Conflict of interestC.A. Schmitt received travel support, honoraria and consulting fees from Abbvie, AstraZeneca, Bayer, Bristol-Myers Squibb/Celgene, Gilead/Kite, Janssen-Cilag, MSD, Novartis, Octapharma, Pierre Fabre, Roche, Sanofi, Takeda and TissUse.
Details
- Language :
- English
- ISSN :
- 1865-5041
- Volume :
- 15
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Memo
- Publication Type :
- Editorial & Opinion
- Accession number :
- 35693203
- Full Text :
- https://doi.org/10.1007/s12254-022-00813-w